When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AMGN - Amgen's AMG 510 shows encouraging action in early-stage tumor study
Amgen Inc.
Preliminary data from an open-label Phase 1 clinical trial evaluating Amgen's (NASDAQ:AMGN) KRASG12C inhibitor AMG 510 in patients with solid tumors showed a positive effect. The data were presented at ASCO in Chicago.
More news on: Amgen Inc., Mirati Therapeutics, Inc., Healthcare stocks news,